User:Mr. Ibrahem/Daptomycin

From Wikipedia, the free encyclopedia

Mr. Ibrahem/Daptomycin
Clinical data
Trade namesCubicin, Cubicin RF, others
Other namesLY 146032
AHFS/Drugs.comMonograph
License data
Pregnancy
category
Routes of
administration		Intravenous
Drug classLipopeptide, antibiotic[2]
Legal status
Legal status
Pharmacokinetic data
Bioavailabilityn/a
Protein binding90–95%
MetabolismRenal (speculative)[7]
Elimination half-life7–11 hours (up to 28 hours in renal impairment)
ExcretionKidney (78%; primarily as unchanged drug); faeces (5.7%)
Identifiers
  • N-Decanoyl-L-tryptophyl-L-asparaginyl-L-aspartyl-L-threonylglycyl-L-ornithyl-L-aspartyl-D-alanyl-L-aspartylglycyl-D-seryl-threo-3-methyl-L-glutamyl-3-anthraniloyl-L-alanine[egr]1-lactone
Chemical and physical data
FormulaC72H101N17O26
Molar mass1620.693 g·mol−1
  • InChI=1S/C72H101N17O26/c1-5-6-7-8-9-10-11-22-53(93)81-44(25-38-31-76-42-20-15-13-17-39(38)42)66(108)84-45(27-52(75)92)67(109)86-48(30-59(102)103)68(110)89-61-37(4)115-72(114)49(26-51(91)40-18-12-14-19-41(40)74)87-71(113)60(35(2)24-56(96)97)88-69(111)50(34-90)82-55(95)32-77-63(105)46(28-57(98)99)83-62(104)36(3)79-65(107)47(29-58(100)101)85-64(106)43(21-16-23-73)80-54(94)33-78-70(61)112/h12-15,17-20,31,35-37,43-50,60-61,76,90H,5-11,16,21-30,32-34,73-74H2,1-4H3,(H2,75,92)(H,77,105)(H,78,112)(H,79,107)(H,80,94)(H,81,93)(H,82,95)(H,83,104)(H,84,108)(H,85,106)(H,86,109)(H,87,113)(H,88,111)(H,89,110)(H,96,97)(H,98,99)(H,100,101)(H,102,103)/t35-,36-,37-,43+,44+,45+,46+,47+,48+,49+,50-,60+,61+/m1/s1 --> ☒N
  • Key:DOAKLVKFURWEDJ-RWDRXURGSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Daptomycin, sold under the brand name Cubicin among others, is an antibiotic used to treat serious infections caused by Gram-positive organisms, including methicillin-resistant Staphylococcus aureus (MRSA).[2] It is given by injection into a vein.[2]

Common side effects include diarrhea, headache, rash, liver problems, muscle damage, and itchiness.[2] Other side effects include fungal infections, pain at the site of injection, and allergic reactions.[8] It is a lipopeptide and works by altering the cell membrane of certain bacteria.[2]

Daptomycin approved for medical use in the United States in 2003 and Europe in 2006.[2][8] It is a naturally occurring from Streptomyces roseosporus.[9] It was removed from the World Health Organization's List of Essential Medicines in 2019.[10][11] It; however, is critically important for human medicine.[12]

References[edit]

  1. ^ a b "Daptomycin Use During Pregnancy". Drugs.com. 3 December 2019. Archived from the original on 21 October 2020. Retrieved 28 August 2020.
  2. ^ a b c d e f g h "Daptomycin Monograph for Professionals". Drugs.com. Archived from the original on 4 March 2021. Retrieved 22 July 2021.
  3. ^ "Cubicin 350 mg powder for solution for injection or infusion - Summary of Product Characteristics (SmPC)". (emc). 24 August 2018. Archived from the original on 4 August 2020. Retrieved 28 August 2020.
  4. ^ "Cubicin- daptomycin injection, powder, lyophilized, for solution". DailyMed. 18 December 2018. Archived from the original on 25 March 2021. Retrieved 28 August 2020.
  5. ^ "Cubicin RF- daptomycin injection, powder, lyophilized, for solution". DailyMed. 18 December 2018. Archived from the original on 26 March 2021. Retrieved 28 August 2020.
  6. ^ "Cubicin". European Medicines Agency. 17 September 2018. Archived from the original on 26 October 2020. Retrieved 28 August 2020.
  7. ^ Woodworth JR, Nyhart EH, Brier GL, Wolny JD, Black HR (February 1992). "Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers". Antimicrobial Agents and Chemotherapy. 36 (2): 318–25. doi:10.1128/aac.36.2.318. PMC 188435. PMID 1318678.
  8. ^ a b "Cubicin". Archived from the original on 26 October 2020. Retrieved 22 July 2021.
  9. ^ Nieder, Rolf; Benbi, Dinesh K.; Reichl, Franz X. (10 January 2018). Soil Components and Human Health. Springer. p. 64. ISBN 978-94-024-1222-2. Archived from the original on 29 August 2021. Retrieved 22 July 2021.
  10. ^ World Health Organization (2019). Executive summary: the selection and use of essential medicines 2019: report of the 22nd WHO Expert Committee on the selection and use of essential medicines. Geneva: World Health Organization. hdl:10665/325773. WHO/MVP/EMP/IAU/2019.05. License: CC BY-NC-SA 3.0 IGO.
  11. ^ World Health Organization (2019). The selection and use of essential medicines: report of the WHO Expert Committee on Selection and Use of Essential Medicines, 2019 (including the 21st WHO Model List of Essential Medicines and the 7th WHO Model List of Essential Medicines for Children). Geneva: World Health Organization. hdl:10665/330668. ISBN 9789241210300. ISSN 0512-3054. WHO technical report series;1021.
  12. ^ World Health Organization (2019). Critically important antimicrobials for human medicine (6th revision ed.). Geneva: World Health Organization. hdl:10665/312266. ISBN 9789241515528.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Daptomycin&oldid=1159550517"